Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 1904Breast Neoplasms 1423Carcinoma, Non-Small-Cell Lung 1176Prostatic Neoplasms 740Colorectal Neoplasms 685Neoplasm Metastasis 623Multiple Myeloma 546Melanoma 527Ovarian Neoplasms 455Lung Neoplasms 446Lymphoma, Non-Hodgkin 385Lymphoma 374Recurrence 371Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 253Head and Neck Neoplasms 246Glioblastoma 219Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 182Squamous Cell Carcinoma of Head and Neck 181Carcinoma 175Uterine Cervical Neoplasms 174Urinary Bladder Neoplasms 174Advanced Solid Tumors 160

Interventions

enzalutamide 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Biochemically Recurrent Prostate Cancer × Clear all
NCT05526248 2026-03-11

ARAMON

Bayer

Phase 2 Completed
28 enrolled 14 charts
Genitourinary

Biochemically Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡